Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients - sprookjes - yvandenbroek - TriplyDB

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

http://www.wikidata.org/entity/Q27487949

about

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase Hepatitis C virus protease inhibitor-resistance mutations: our experience and review Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy KASL clinical practice guidelines: management of hepatitis C Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals Virologic Tools for HCV Drug Resistance Testing Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance New era for management of chronic hepatitis C virus using direct antiviral agents: A review Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy Viral quasispecies evolution Direct acting antivirals for the treatment of chronic viral hepatitis Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance Temporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected Individual Counteracting Quasispecies Adaptability: Extinction of a Ribavirin-Resistant Virus Mutant by an Alternative Mutagenic Treatment Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase Attenuation of 40S ribosomal subunit abundance differentially affects host and HCV translation and suppresses HCV replication Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing N-substituted benzyl matrinic acid derivatives inhibit hepatitis C virus (HCV) replication through down-regulating host heat-stress cognate 70 (Hsc70) expression Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA.Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6 Hepatitis C virus transmission bottlenecks analyzed by deep sequencing.HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma.

P2860

Q21132564-F8B9C0B3-55EB-4610-B96C-A890E8A75764 Q24314907-1D06E7EA-6176-4414-8BE0-EC6B8FC8C872 Q24628717-E27798DD-A0A6-4849-A3CF-11A6172B228E Q26700073-08E4C41D-C794-497C-904D-C147A81B818E Q26752471-7A98D8E0-21A6-4DF2-8C73-38FF4C72F39A Q26773321-E68E0D57-632F-4787-98EB-0EAB04030E76 Q26774374-DFE24FE2-89C1-49BE-A899-63D89B80C74C Q26775825-915DD0FC-01AD-48D2-83B4-A3A39F8E9A92 Q26782405-58D557A4-4F0D-4422-A19A-707D40A10F50 Q26783056-C9E93F52-E3CC-4C0C-B799-CE3066FEADCA Q26800050-D9DCCD79-B774-46D1-AE0E-6FF8E719378B Q26827322-940EE647-5169-475D-96FC-F3F04D1AF457 Q26853500-5FE05517-FD60-4200-8A5E-7125BFD62730 Q27013917-5497BADC-FF77-4E1F-B034-FEC1AFE3A1EF Q27022216-1051EB35-70C7-484E-8DCE-90FBE25D1C9A Q27469038-5FA78439-5A9F-411D-9DF3-CDB1634561F2 Q27488198-A776326B-8C71-44A1-864B-709D172E0EA5 Q27488361-8B3DA83B-DC9A-4BF4-9500-F494C7C63C4F Q27490222-9FA3E274-A5D6-4FC8-88D3-6D98537B4526 Q27665956-B6C5BD90-B3B6-404C-9642-2800217FA1B3 Q28079102-A977DEB4-0F3C-4521-889C-9CC84D8C7D13 Q28477175-8073400F-11D9-4660-A83E-60654719CFE6 Q28480947-845FC1D9-3DC3-401E-B0CB-6F3D7AB88CEC Q28481243-8753AF27-1D21-4BED-B61C-380E16344487 Q28481622-1D17114F-9943-4E36-8597-607A0D9791A1 Q28482493-B16BF877-0E9C-4187-9255-EAFDA219B375 Q28488041-9D36ED67-D108-4502-A372-A24675EF1462 Q28534965-D28BAC92-CD92-4272-87CE-A5616C717E3A Q28538943-85D2C0E0-49D7-476C-A7C6-20DF3D28D39E Q28541048-F9BD4610-3D59-42D6-B1E5-64BFCA13DCD2 Q28552134-E6A624F2-0DC9-4F68-AF18-DD1748766116 Q28652352-974472E9-44F8-478E-BBD6-149522BC2F40 Q30355190-68E27BE9-3C09-469C-9C61-2EDB9AD05D2D Q31042796-0E4588AF-7AC6-47E2-9842-4CD9BCA17E76 Q33622640-96C0E255-4BDD-48B7-AD50-1FA113755B9B Q33622970-CD442BD9-551F-420B-A108-724ED647AD1B Q33672648-2A94F512-8FC8-4761-8BDA-EAC05E6556B8 Q33826766-53235083-3AEB-4E0D-B7E1-C9C4F019E3DA Q33877425-842682A3-BA74-46C9-B2E8-C6A4C58D4647 Q33982230-03558BFE-8BA0-4907-A116-1BDEE91CE9F4

P2860

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

http://www.wikidata.org/entity/Q27487949

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Naturally occurring dominant r ...... rs in treatment-naïve patients

@ast

Naturally occurring dominant r ...... rs in treatment-naïve patients

@en

Naturally occurring dominant r ...... rs in treatment-naïve patients

@nl

type

label

Naturally occurring dominant r ...... rs in treatment-naïve patients

@ast

Naturally occurring dominant r ...... rs in treatment-naïve patients

@en

Naturally occurring dominant r ...... rs in treatment-naïve patients

@nl

prefLabel

Naturally occurring dominant r ...... rs in treatment-naïve patients

@ast

Naturally occurring dominant r ...... rs in treatment-naïve patients

@en

Naturally occurring dominant r ...... rs in treatment-naïve patients

@nl

P1433

Q27487949-B2B0E6DC-344D-4D0B-96EE-1EEADD8CA13A

P1476

Q27487949-E6BE27EC-6BBE-4597-9CF9-09157EF2D407

P2093

Q27487949-04CEE52F-1A01-4984-8A45-8DFF9448B1F2

Q27487949-0A1B73C7-C379-484A-89C5-124106D21050

Q27487949-0BC04AFE-FF8A-45B7-B5FD-1E43174AF21D

Q27487949-14F2354A-6657-497E-B466-5EAC04F6E617

Q27487949-1A4C0E34-3E8A-40AB-80E0-B3AC744B8FF4

Q27487949-29D4A7E2-DB36-4822-88E0-7FC7D08B3167

Q27487949-3E922703-6E6F-43E7-BC26-4611A41B64B1

Q27487949-465A6964-74EC-4EA4-AA1D-7B3680E90A6D

Q27487949-52A60D09-82E8-4E78-8399-F1250628347C

Q27487949-57A2F41A-AE29-460A-977B-0B0AEE96FC4F

P2860

Q27487949-05B13D4C-19D9-4F33-8B97-B5AC16749B4A

Q27487949-0B6F8B2F-7379-4FB8-BBC6-63A1FCCCB185

Q27487949-17E66282-316E-4C09-9D15-35786D67BE81

Q27487949-17F4B5C8-42C5-4CF0-87E0-B5ED5575DC71

Q27487949-1E091AED-B67E-4F41-BCA3-547C4F7D31A9

Q27487949-1F2D96DB-D9A9-4F6F-8C7D-D0AEB249E164

Q27487949-22B23775-FE0E-4885-8B96-387DF6D71811

Q27487949-2C36DE78-C0FD-4645-B36F-BD1CD7692E7E

Q27487949-416E224D-CAD0-47A6-B644-FED41F541F85

Q27487949-4246F1DB-E7E3-4C03-A059-F07A475DD800

P304

Q27487949-4916BF1B-B78A-49BF-A4EB-C77B3CDDE303

P31

Q27487949-9AEBF311-09F7-4D30-90DF-3BAD88062B1D

P3181

Q27487949-BCD2E32C-F9C6-43E4-A9E1-03B9DD555328

P356

Q27487949-EE929464-32A9-4537-BBB6-D08475C53AB7

P407

Q27487949-7FA849BE-7D90-4B64-8C88-48EE945D4421

P433

Q27487949-322C55DE-92F0-4172-9991-FDAF099BD8DE

P478

Q27487949-F35AD946-DE4E-4149-ACAE-51A76308CB5B

P50

Q27487949-0F1462F4-AF5C-4458-AB36-F090027C09A5

Q27487949-2E35A59C-C89C-4887-AC69-FF775F3FB5B2

Q27487949-58EC3654-95C5-4C51-8B93-A2C157DBF93B

Q27487949-83F4CBCC-1462-45C3-86EC-A48832B6BAB2

Q27487949-850CF0BD-50C3-4836-B21C-6B358F3CBB02

Q27487949-ADD93C94-536A-42FB-8818-A104987D972B

Q27487949-D1429272-BD9D-4A67-A53E-F554634B9882

Q27487949-D6798CFF-8E0A-40BA-BEEE-C451652696A7

Q27487949-EC3E0A14-DF35-40DA-863E-9A1F6FE23B1D

Q27487949-ED50D803-EA61-4F49-9F81-F2574E7EB7AF

P577

Q27487949-BEF8904C-F048-4E2F-B6C9-DE03F786F758

P5875

Q27487949-EB199084-B3F9-4149-880F-99F988FE7FE0

P698

Q27487949-8C87F941-B753-476A-9D15-4383CD4F8E18

P932

Q27487949-404EB929-0B58-4012-9F17-C3FCF08918FA

P3181

P356

P1433

P1476

Naturally occurring dominant r ...... rs in treatment-naïve patients

@en

P2093

Aaron M Berlin

http://www.w3.org/2001/XMLSchema#string

Andreas Cerny

http://www.w3.org/2001/XMLSchema#string

Andrew Berical

http://www.w3.org/2001/XMLSchema#string

Andrew D Roberts

http://www.w3.org/2001/XMLSchema#string

Andrew H Talal

http://www.w3.org/2001/XMLSchema#string

Arne Schneidewind

http://www.w3.org/2001/XMLSchema#string

Arthur Y Kim

http://www.w3.org/2001/XMLSchema#string

Bongshin Lee

http://www.w3.org/2001/XMLSchema#string

Bruce W Birren

http://www.w3.org/2001/XMLSchema#string

Chinnappa Kodira

http://www.w3.org/2001/XMLSchema#string

P2860

The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

Viral Sequence Evolution in Acute Hepatitis C Virus Infection

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

P304

1769-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

513384

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/HEP.22549

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Bruce D. Walker

Julian Schulze zur Wiesch

Christopher Birch

David Heckerman

Raymond T Chung

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23489955

http://www.w3.org/2001/XMLSchema#string

P698

19026009

http://www.w3.org/2001/XMLSchema#string

P932

2645896

http://www.w3.org/2001/XMLSchema#string